Charlie Mills Salary: What the Medline Chairman Earns

Quick answer

Charlie Mills' salary has never been publicly disclosed — not during his 26 years as Medline's CEO (1997–2023), and not since he became chairman. Medline was a private company for nearly that entire run, and private companies don't publish executive pay. The honest answer to "what does he earn" is that it never mattered: his $11 billion fortune (Forbes 400, 2026) comes from owning Medline, not from being paid by it.

This is the owner-operator model in its purest form. While hired-gun CEOs negotiate pay packages, Mills spent 26 years growing the value of his own stake — from a company doing about $600 million in annual sales to one doing $25.5 billion. For the equity story behind the number, see Charlie Mills' net worth and how he made his money.

The private-company black box: 1997–2023

Medline went private in 1977 — five years after a brief stint as a public company — and stayed private until December 2025. That 48-year stretch as a private firm means there are no proxy statements, no 10-K compensation tables, and no disclosed pay figures for Charlie Mills' entire CEO tenure.

What we know about the era is structural, not numerical. As a significant owner-CEO, Mills' incentives were aligned with equity value, not annual pay. Family-business CEOs in his position typically take moderate salaries plus distributions tied to ownership — but Medline never confirmed any figure, and no credible outlet has ever reported one. Anyone quoting a specific salary number for his CEO years is guessing.

The contrast with public-company peers is instructive: a hired CEO growing a company 40-fold would typically extract hundreds of millions in stock awards along the way. Mills didn't need the awards. He already owned the stock.

Chairman since 2023: what the role pays — eventually

Mills transitioned from CEO to chairman in 2023 after 26 years running the company, with Jim Boyle taking over as CEO — Boyle is the executive who rang the Nasdaq opening bell at the IPO. As chairman of a now-public company (Nasdaq: MDLN), Mills' board compensation will eventually appear in Medline's proxy statements.

As of this writing, no such figure has been published. Public-company chairs commonly receive a cash retainer plus equity awards, but the specific package for Mills — and whether a man worth $11 billion even takes a meaningful retainer — will only be known when Medline files its first full-year proxy as a listed company. We will update this article when that filing lands.

There is also a governance wrinkle worth noting: Mills is not an independent chairman but the controlling family's representative — the largest single shareholder's man in the boardroom. In that role, his compensation matters less as an incentive (he hardly needs one) than as a signal of how seriously the public company takes independent oversight alongside family control.

The real paydays: 2021 and 2025

If salary was never the point, liquidity events were. Two transactions converted decades of paper wealth into spendable reality:

The 2021 deal, at a roughly $34 billion valuation, was the first time the family's holding got a market-tested price — and the first large-scale liquidity for a stake built over 55 years. The IPO's equity redemptions then returned capital directly to pre-IPO holders. For an owner, these events dwarf any salary: a single percentage point of a $34 billion valuation is $340 million — more than a lifetime of CEO paychecks.

Going forward, the public listing adds two more potential cash channels that never existed in the private era: open-market share sales (which would appear in SEC insider-trading filings) and dividends, if Medline's board chooses to initiate one. Either would be the first publicly visible cash return to Charlie Mills personally — and either would be reported here when disclosed.

Known vs. unknown: the honest ledger

The ledger tells the story of a particular wealth philosophy: take the equity, skip the spotlight, and let 26 years of compounding do the talking. Mills never needed to negotiate a pay package because he was, in effect, paying himself with the rising value of the company.

The hired-CEO contrast

To grasp how unusual Mills' setup was, compare it with the standard public-company playbook. A hired chief executive brought in to grow a company 40-fold would typically negotiate multimillion-dollar annual packages loaded with stock awards — compensation committees design pay to mimic ownership because the CEO doesn't actually own the place. Over 26 years, that mimicry routinely transfers hundreds of millions of dollars from shareholders to the corner office.

Mills skipped the mimicry and kept the real thing. He didn't need a compensation committee to grant him shares; he already held a founding-family stake. Every dollar of enterprise value he created flowed straight to his own net worth — no vesting schedules, no proxy battles over pay ratios, no headlines about golden parachutes. The trade-off was illiquidity: until 2021, his wealth was trapped in a private company he couldn't easily sell. The $34 billion buyout and the $6.26 billion IPO were the releases of 26 years of stored-up value.

What the first proxy will reveal

Medline's debut as a public company means the black box is opening — slowly. U.S. listed companies must disclose executive and director compensation in annual proxy statements, so Medline's first full-year proxy will show, for the first time, what the chairman of a $25.5-billion-revenue medical supplier actually takes home: cash retainer, committee fees, and any stock awards granted to Charlie Mills as a director.

Two things are worth watching when it lands. First, whether Mills takes a standard independent-chair package or a reduced one — billionaire founders often waive or minimize board pay. Second, how his disclosed pay compares with CEO Jim Boyle's package, which will reveal how the public company values the operator versus the owner. Until then, the only honest number for Charlie Mills' salary remains: undisclosed.

The owner-operator playbook

There's a reason the salary question has a boring answer and the wealth question doesn't. Hired CEOs at public companies routinely earn tens of millions a year in stock awards — compensation designed to mimic ownership. Mills skipped the mimicry and kept the real thing: a founding-family stake in a business doing $25.5 billion in annual sales with 50+ consecutive years of growth.

The 2021 buyout valued that business at ~$34 billion; the 2025 IPO priced it above $38 billion and the market promptly marked it higher. Against numbers like that, a salary — disclosed or not — is a rounding error. Which is presumably why one was never worth disclosing. For the companies behind the fortune, see what Charlie Mills owns.

Frequently asked questions